Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Oncobax®-AK in Patients With Advanced Solid Tumors
Sponsor: EverImmune
Summary
Akkermansia muciniphila is a naturally occurring bacterium found in the healthy human gastrointestinal tract. Analysis of the gut microbiota of NSCLC or RCC patients shows that the presence of Akkermansia is associated with the clinical efficacy of immunotherapy. In preclinical models, oral administration of the Akkermansia p2261 strain reverses resistance to PD-1 blockade. In the clinical setting, it is therefore hypothesized that the oral administration of Oncobax®-AK to cancer patients under immunotherapy, but whose gut microbiota is deficient in Akkermansia will restore / improve the efficacy of immunotherapy in patients with NSCLC or RCC.
Official title: A Phase 1/2 Study of Oncobax®-AK Administered in Combination With Immunotherapy To Patients With Advanced Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
122
Start Date
2022-10-01
Completion Date
2026-06
Last Updated
2023-05-19
Healthy Volunteers
No
Interventions
Live Bacterial Product - Akkermansia muciniphila
Oral administration of Oncobax-AK to patients deficient in Akkermansia by stool metagenomic analysis.
Locations (4)
CHU Ambroise Paré
Mons, Belgium
Centre Georges Francois Leclerc
Dijon, France
Institut Gustave Roussy
Paris, France
ICANS - Institut de cancérologie Strasbourg
Strasbourg, France